Healthcare Equipment and Supplies
Company Overview of Theralase Technologies Inc.
Theralase Technologies Inc. designs, develops, manufactures, and markets laser technology used in bio-stimulative and bio-destructive clinical applications. The company engages in the production, marketing, and distribution of TLC-1000 and TLC-2000 laser technology for the treatment of chronic pain, neural muscular-skeletal conditions, and wound healing. It is also involved in the commercialization of the patented TLC-3000 photo dynamic compound technology through pre-clinical scientific research, clinical trials, and technology development in the treatment of cancers for oncological applications and in the destruction of bacteria, viruses, and microbial pathogens; and research and developme...
1945 Queen Street East
Toronto, ON M4L 1H7
Key Executives for Theralase Technologies Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $150.0K
Chief Financial Officer
Total Annual Compensation: $115.0K
Compensation as of Fiscal Year 2013.
Theralase Technologies Inc. Key Developments
Theralase Technologies Inc. Discovers Lead Anti-Cancer Drug, TLD-1433, Emits Fluorescent Signature When Light Activated in Non-Muscle Invasive Bladder Cancer Animal Model
May 14 15
Theralase Technologies Inc. has discovered that its lead anti-cancer drug, TLD-1433, emits a fluorescent signature when light activated in a Non-Muscle Invasive Bladder Cancer ('NMIBC') animal model. The advantages of this discovery are three fold: It can be used as a diagnostic tool for the oncologist to detect the presence of cancer cells and micro-metastases too small to be seen by the human eye. It can be used to determine sufficient uptake of TLD-1433 into the cancer cells. After light activation, it can determine if the cancer cells that have absorbed the drug have been destroyed. The company intends to use this new discovery in the treatment of NMIBC. Clinical Treatment Protocol of NMBIC with Photo Dynamic Therapy: Intravesical installation of TLD-1433 into the bladder via cystoscope. Allow approximately sixty minutes for the drug to diffuse into the bladder cancer cells. Flush the bladder and refill with water. Visual analysis by the uro-oncologist to check for fluorescence to indicate the presence of cancer cells, their specific location and whether sufficient quantities of the drug have been absorbed to proceed to light activation. Light activation for approximately thirty minutes. Post treatment analysis to check for no fluorescence indicating that all bladder cancer cells that absorbed the drug have been destroyed.
Theralase Manufactures Light-Activated, Anti-Cancer Drug, TLD-1433
May 12 15
Theralase Technologies Inc. announced that it has successfully manufactured its lead, light-activated, anti-cancer drug, TLD-1433, specifically developed for the treatment of cancer, to high purity levels. Drugs intended for in human clinical applications, such as TLD-1433, must be manufactured in accordance with Good Manufacturing Practices (GMP) standards. To achieve GMP standards, the normal manufacturing process involves "scaling-up" the production from small quantities to successively larger quantities to optimize the purity and yield of the drug to arrive at a commercial grade product, suitable for human applications. In April 2015, the company announced the completion of the manufacture of its lead anti-cancer drug in pre-commercial quantities. The company has now completed another critical step, optimization of the manufacturing process to produce high purity TLD-1433. This latest high purity batch will be used to complete the Good Laboratory Practices (GLP) toxicology analyses, a key component of the Clinical Trial Application (CTA) that the company plans to file with Health Canada (HC) in third quarter of 2015. The company can now focus on completion of the final and most important step, manufacture of a GMP batch of TLD-1433 suitable for use in human clinical applications. Pending HC approval of the CTA, the Company plans to enroll patients in a Phase Ib clinical study for Non Muscle Invasive Bladder Cancer (NMIBC) to prove the safety, tolerability and efficacy of its anti-cancer technology in a human population in the fourth quarter of 2014. Production of a GMP batch of TLD-1433 provides enough anti-cancer drug to support Theralase's entire clinical program through to commercialization in the treatment of patients with NMIBC, while also providing sufficient PDC for the company to further investigate other cancer indications.
Theralase Technologies Inc. Reports Earnings Results for the Year Ended December 31, 2014
May 1 15
Theralase Technologies Inc. reported earnings results for the year ended December 31, 2014. For the year, the company’s total revenue increased 15% to CAD 1,380,604 from CAD 1,203,620 year over year. The net loss for the year was CAD 2,587,542 compared to a net loss of CAD 1,152,209 a year ago. The net loss is a reflection of the ongoing commitment of Theralase to invest in the next generation of therapeutic laser technology and anti-cancer treatment technology, partly funded from existing therapeutic laser sales.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|